Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Top 20 Shareholders

Share Price

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Investor Centre

Clinical Trial

Webinars

Pipeline

Home

Contact

Team

Company Overview

Board

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Montserrat

Amplia Therapeutics Limited

Amplia has today announced that six patients in the Phase 2a ACCENT trial investigating narmafotinib in the treatment of advanced pancreatic cancer have now recorded confirmed partial responses, indicating that the combination of narmafotinib with the chemotherapies gemcitabine and Abraxane® is sufficiently active to support continuation of the trial.

The ACCENT trial can now proceed to recruit the next cohort of 24 patients. A total of 50 patients are planned for the Phase 2a ACCENT trial, and recruitment will begin at the existing open trial sites in Australia and South Korea.

Amplia CEO and MD Dr Chris Burns commented:

“Having now confirmed our sixth PR, we will move forward with recruiting the remaining 24 patients for the trial. We are actively working with our clinical sites to ensure seamless reopening of enrolment with the goal of completing recruitment by the end of March 2025. As always, we thank the patients and their loved ones for being involved with this trial"

Click link below to read the full ASX Release.

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial